Combinatorial CBS and NAC exhibit broad-spectrum anti-CoVs potency (IMAGE)
Caption
Combinatorial CBS and NAC exhibit broad-spectrum anti-CoVs potency both in vitro and in vivo. (A) Scheme depicting the therapeutic treatment via oral administration of vehicle, CBS (300 mg/kg) or BSS (300 mg/kg), NAC (370 mg/kg) and CBS (300 mg/kg)+3NAC (370 mg/kg) or BSS (300 mg/kg)+3NAC (405 mg/kg), given at Day -2, -1, 0 and 1 and the hamsters were challenged by virus at Day 0; Tissue samples were collected at two days after infection. (B) Viral yield in lung tissue of hamster receiving treatment of vehicle, CBS, NAC, and CBS+3NAC. (C) Viral yield in lung tissue of hamster receiving treatment of vehicle, BBS, and BSS+3NAC. (D) Cytokine IL-6 gene expression level. (E) CBS+3NAC suppressed replication of human-pathogenic coronaviruses in human cellular models in a dose-dependent manner, specifically for SARS-CoV-2 in Vero E6 cells; SARS-CoV-2 (B.1.1.7 variant) in Vero E6 cells; MERS-CoV in Vero E6 cell and HCoV-229E in HELF cell.
Credit
The University of Hong Kong
Usage Restrictions
This work is licensed for non-commercial, non-exclusive, one-time usage with attribution to the copyright holder.
License
Original content